R P L (India) Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 22 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.75 Cr
as on 24-10-2024
- Satisfied Charges ₹ 6.55 M
as on 24-10-2024
- Revenue 88.18%
(FY 2023)
- Profit 412.82%
(FY 2023)
- Ebitda 80.39%
(FY 2023)
- Net Worth 30.17%
(FY 2023)
- Total Assets 27.96%
(FY 2023)
About R P L (India) Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.75 Cr. The company has closed loans amounting to ₹6.55 M, as per Ministry of Corporate Affairs (MCA) records.
Vikas Bablani, Ritu Bablani, and Shray Bablani serve as directors at the Company.
- CIN/LLPIN
U24239DL2002PTC115402
- Company No.
115402
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at R P L (India) Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Bablani  | Director | 31-Mar-2003 | Current |
| Ritu Bablani | Director | 17-May-2002 | Current |
| Shray Bablani | Director | 04-Aug-2016 | Current |
Financial Performance of R P L (India) Pharmaceuticals.
R P L (India) Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 88.18% increase. The company also saw a substantial improvement in profitability, with a 412.82% increase in profit. The company's net worth Soared by an impressive increase of 30.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R P L (India) Pharmaceuticals?
Unlock access to R P L (India) Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Feb 2023 | ₹4.00 M | Open |
Others Creation Date: 08 Jan 2021 | ₹4.00 M | Open |
Others Creation Date: 22 Feb 2006 | ₹4.95 Cr | Open |
How Many Employees Work at R P L (India) Pharmaceuticals?
R P L (India) Pharmaceuticals has a workforce of 13 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R P L (India) Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R P L (India) Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
